Foamix Pharmaceuticals (FOMX) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Share on StockTwits

Foamix Pharmaceuticals (NASDAQ:FOMX) announced its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04), Morningstar.com reports. The company had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.95 million. Foamix Pharmaceuticals had a negative net margin of 2,062.95% and a negative return on equity of 103.92%.

NASDAQ:FOMX traded down $0.02 during trading hours on Wednesday, hitting $3.13. The company’s stock had a trading volume of 313,967 shares, compared to its average volume of 332,429. The firm has a market capitalization of $174.52 million, a PE ratio of -1.84 and a beta of 1.60. Foamix Pharmaceuticals has a 52-week low of $3.06 and a 52-week high of $7.60.

In other Foamix Pharmaceuticals news, insider Matthew T. Wiley bought 13,440 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The shares were purchased at an average price of $3.76 per share, with a total value of $50,534.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 9,311 shares of company stock worth $34,916 in the last three months. 2.95% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. Worth Venture Partners LLC purchased a new position in Foamix Pharmaceuticals in the fourth quarter valued at $48,000. Steward Partners Investment Advisory LLC increased its holdings in Foamix Pharmaceuticals by 29.4% in the first quarter. Steward Partners Investment Advisory LLC now owns 17,155 shares of the specialty pharmaceutical company’s stock valued at $64,000 after buying an additional 3,900 shares during the last quarter. Van ECK Associates Corp increased its holdings in Foamix Pharmaceuticals by 75.1% in the fourth quarter. Van ECK Associates Corp now owns 19,752 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 8,474 shares during the last quarter. Credit Suisse AG purchased a new position in Foamix Pharmaceuticals in the third quarter valued at $194,000. Finally, Federated Investors Inc. PA purchased a new position in Foamix Pharmaceuticals in the third quarter valued at $287,000. 59.61% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have recently issued reports on FOMX. Cantor Fitzgerald reiterated a “buy” rating and issued a $15.00 price objective on shares of Foamix Pharmaceuticals in a research note on Tuesday, April 2nd. Cowen set a $30.00 price objective on Foamix Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $14.75.

ILLEGAL ACTIVITY WARNING: This story was first reported by Equities Focus and is the property of of Equities Focus. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.equitiesfocus.com/2019/05/09/foamix-pharmaceuticals-fomx-releases-quarterly-earnings-results-misses-expectations-by-0-04-eps.html.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.

See Also: Moving Average (MA)

Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.